162 related articles for article (PubMed ID: 8150758)
1. Cefepime as treatment for osteomyelitis and other severe bacterial infections.
Jauregui L; Matzke D; Scott M; Minns P; Hageage G
J Antimicrob Chemother; 1993 Nov; 32 Suppl B():141-9. PubMed ID: 8150758
[TBL] [Abstract][Full Text] [Related]
2. Cefepime: overview of activity in vitro and in vivo.
Grassi GG; Grassi C
J Antimicrob Chemother; 1993 Nov; 32 Suppl B():87-94. PubMed ID: 8150771
[TBL] [Abstract][Full Text] [Related]
3. Low-dosage cefepime as treatment for serious bacterial infections.
Giamarellou H
J Antimicrob Chemother; 1993 Nov; 32 Suppl B():123-32. PubMed ID: 8150755
[TBL] [Abstract][Full Text] [Related]
4. Clinical applications of a new parenteral antibiotic in the treatment of severe bacterial infections.
Holloway WJ; Palmer D
Am J Med; 1996 Jun; 100(6A):52S-59S. PubMed ID: 8678098
[TBL] [Abstract][Full Text] [Related]
5. A non-comparative, multicentre study of cefepime in the treatment of serious bacterial infections.
Mouton Y; Chidiac C; Humbert G; Leroy J; Veyssier P; Modai J; Bertrand A; Dellamonica P; Micoud M; Stahl JP
J Antimicrob Chemother; 1993 Nov; 32 Suppl B():133-40. PubMed ID: 8150757
[TBL] [Abstract][Full Text] [Related]
6. International comparative study of cefepime and ceftazidime in the treatment of serious bacterial infections.
Hoepelman AI; Kieft H; Aoun M; Kosmidis J; Strand T; Verhoef J; Gillespie SH; Riddell J; Varghese G; Meunier F
J Antimicrob Chemother; 1993 Nov; 32 Suppl B():175-86. PubMed ID: 8150761
[TBL] [Abstract][Full Text] [Related]
7. [Cefepime in the treatment of osteomyelitis caused by Gram negative bacilli].
Barberán J; Gomis M; Sánchez B; Hernández-Salván J; García Del Salto L; Carroquino G; González F; Hernández M
Rev Esp Quimioter; 2000 Dec; 13(4):366-73. PubMed ID: 11498702
[TBL] [Abstract][Full Text] [Related]
8. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Jones RN; Sader HS; Fritsche TR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
[TBL] [Abstract][Full Text] [Related]
9. Activity of cefepime compared with other antibiotics against gram-positive bacteria and cefuroxime-resistant gram-negative bacteria.
Wang FD; Liu IM; Liu CY
Zhonghua Yi Xue Za Zhi (Taipei); 1998 Jul; 61(7):408-13. PubMed ID: 9699393
[TBL] [Abstract][Full Text] [Related]
10. Cefepime: a new fourth-generation cephalosporin.
Okamoto MP; Nakahiro RK; Chin A; Bedikian A; Gill MA
Am J Hosp Pharm; 1994 Feb; 51(4):463-77; quiz 541-2. PubMed ID: 8017411
[TBL] [Abstract][Full Text] [Related]
11. In-vitro antibacterial activity of cefepime: a multicentre study.
Duval J; Soussy CJ; Acar JF; Bergogne-Bérézin E; Cluzel R; Thabaut A; Courvalin P; Grès JJ; Rollin C
J Antimicrob Chemother; 1993 Nov; 32 Suppl B():55-61. PubMed ID: 8150767
[TBL] [Abstract][Full Text] [Related]
12. Antibiotic susceptibility of bacteria most commonly isolated from bone related infections: the role of cephalosporins in antimicrobial therapy.
Jones ME; Karlowsky JA; Draghi DC; Thornsberry C; Sahm DF; Nathwani D
Int J Antimicrob Agents; 2004 Mar; 23(3):240-6. PubMed ID: 15164964
[TBL] [Abstract][Full Text] [Related]
13. A non-comparative study of the efficacy and tolerance of cefepime in combination with amikacin in the treatment of severe infections in patients in intensive care.
Gouin F; Papazian L; Martin C; Albanese J; Durbec O; Domart Y; Veyssier P; Leroy J; Grès JJ; Rollin C
J Antimicrob Chemother; 1993 Nov; 32 Suppl B():205-14. PubMed ID: 8150764
[TBL] [Abstract][Full Text] [Related]
14. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.
Zhanel GG; Lam A; Schweizer F; Thomson K; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Noreddin AM; Karlowsky JA
Am J Clin Dermatol; 2008; 9(4):245-54. PubMed ID: 18572975
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006).
Fritsche TR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2008 May; 61(1):86-95. PubMed ID: 18385000
[TBL] [Abstract][Full Text] [Related]
16. Cefepime monotherapy for the empirical treatment of fever in granulocytopenic cancer patients.
Eggimann P; Glauser MP; Aoun M; Meunier F; Calandra T
J Antimicrob Chemother; 1993 Nov; 32 Suppl B():151-63. PubMed ID: 8150759
[TBL] [Abstract][Full Text] [Related]
17. A new therapeutic option for the treatment of pneumonia.
McCabe R; Chirurgi V; Farkas SA; Haddow A; Heinz G; Greene S
Am J Med; 1996 Jun; 100(6A):60S-67S. PubMed ID: 8678099
[TBL] [Abstract][Full Text] [Related]
18. Cefepime.
Cunha BA; Gill MV
Med Clin North Am; 1995 Jul; 79(4):721-32. PubMed ID: 7791419
[TBL] [Abstract][Full Text] [Related]
19. Open study of ceftazidime in serious infections due to multiply-resistant bacteria.
Pechère JC; Delisle R
J Antimicrob Chemother; 1983 Jul; 12 Suppl A():181-8. PubMed ID: 6352619
[TBL] [Abstract][Full Text] [Related]
20. Randomized comparative study of cefepime and cefotaxime in the treatment of acute obstetric and gynaecological infections.
Newton ER; Yeomans ER; Pastorek JG; Soper DE; Hemsell DL
J Antimicrob Chemother; 1993 Nov; 32 Suppl B():195-204. PubMed ID: 8150763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
